REG - Genflow Biosciences - Final Results

Genflow BiosciencesAnnouncement

24/04/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230424:nRSX1383Xa&default-theme=true

RNS Number : 1383X  Genflow Biosciences PLC  24 April 2023

 

PRESS RELEASE

24 April 2023

Genflow Biosciences Plc

("Genflow" or "the Company")

FINAL RESULTS

Genflow (LSE: GENF) is pleased to announce its final results for the year
ended 31 December 2022. The Annual Report is available to view on the
Company's website at www.genflowbio.com (http://www.genflowbio.com)

The Company will post the Annual Report to shareholders and provide notice for
its Annual General Meeting in the coming weeks.

Genflow is a UK-based biotechnology company focused on longevity and the
development of therapies to counteract the effects of aging and diseases
associated with advanced age.  It is the first longevity biotechnology
company to list in Europe and seeks to be a reference company in the European
longevity sector.

Market Abuse Regulation (MAR) Disclosure

The information communicated in this announcement is inside information for
the purposes of Article 7 of Regulation 596/2014.

For further information please contact:

 Genflow Biosciences Plc
 Dr Eric Leire             +32 477 495 881

 Chief Executive Officer
 Clear Capital Markets
 Corporate Broker          +44 203 869 6080

 Jonathan Critchley

 

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno-associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

 

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FR NKNBPABKDFQB